Jury verdict favours AZ in Nexium litigation

RNS Number : 0403Z

AstraZeneca PLC

05 December 2014

 



JURY VERDICT FAVOURS ASTRAZENECA IN

NEXIUM ANTITRUST LITIGATION

AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.

AstraZeneca is pleased with the jury's verdict. The Company has always maintained that the plaintiffs' allegations were without merit.

All parties have appellate rights.

Two cases making similar allegations were filed by numerous purchasers in the state court in Pennsylvania and are still pending.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                         [phone] (UK/Global)

Vanessa Rhodes                        [phone] (UK/Global)

Ayesha Bharmal                         [phone] (UK/Global)

Jacob Lund                                 [phone] (Sweden)

Michele Meixell                            + 1 302 885 6351 (US)

Investor Enquiries

Thomas Kudsk Larsen               [phone]    mob: [phone]       

Karl Hård                                     [phone] mob: [phone]

Eugenia Litz                                [phone]    mob: [phone]

Christer Gruvris                          [phone]    mob: [phone]

5 December 2014

-ENDS-

 

END

 

 

MSCEAXASEEELFFF